SCHEMBL2310767

SCHEMBL2310767

CCC(=O)c1cc2c(cc1O)CCN(C(=O)C(F)(F)F)CC2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 6/20 0.49
▸ ESR2 Q92731 6/20 0.49
▸ HMGCR P04035 1/20 0.40
▸ HSP90AB1 P08238 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.36
▸ MAPT P10636 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.35
▸ CA9 Q16790 2/20 0.35
▸ CA12 O43570 1/20 0.34
▸ CA1 P00915 1/20 0.34
▸ CA2 P00918 1/20 0.34
▸ CA7 P43166 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ ABHD6 Q9BV23 1/20 0.34
▸ HPGD P15428 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2310177 0.85 ESR2 (0.52) ESR1ESR2ALDH1A1HDAC6CA9
SCHEMBL2308715 0.79 ESR2 (0.53) ESR2HMGCRHSP90AB1ALDH1A1MAPT
SCHEMBL5334383 0.79 ESR2 (0.55) ESR1ESR2HDAC6CA9CA12
SCHEMBL7838706 0.78 ESR1 (0.39) ESR1ESR2
SCHEMBL29258061 0.76 HMGCR (0.51) HMGCRHSP90AB1ALDH1A1MAPTCA9
SCHEMBL11453172 0.76 HMGCR (0.51) HMGCRHSP90AB1ALDH1A1MAPTCA9
SCHEMBL15828479 0.76 ESR1 (0.55) ESR1ESR2HDAC6CA9CA12
SCHEMBL15828368 0.76 ESR1 (0.55) ESR1ESR2HDAC6CA9CA12
SCHEMBL719456 0.71 ESR1 (0.56) ESR1ESR2HDAC6CA9CA12
SCHEMBL7423360 0.71 ESR1 (0.52) ESR1ESR2ALDH1A1HDAC6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1751163-B1 BENZAZEPINE COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF GLAXO GROUP LTD (GB) 2011-08-10 — — EP disclosed
US-7989444-B2 Compounds having affinity for dopamine D3 receptor and uses thereof GLAXO GROUP LIMITED (GB) 2011-08-02 — — US disclosed
US-20100016287-A1 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ GLAXO GROUP LIMITED (GB) 2010-01-21 — — US disclosed
EP-1751163-A2 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF GLAXO GROUP LIMITED (GB) 2007-02-14 — — EP disclosed
WO-2005118549-A2 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF GLAXO GROUP LIMITED (GB) 2005-12-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016287-A1 COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF\ DRD3, DRD2, SLC6A3 ESR1 607/4885ESR2 775/4885HMGCR 2567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback